Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival

Journal of Heart and Lung Transplantation

Volumn 34, Issue 11, 2015, Pages 1442-1448

  Gallagher, Harry M ^a,b   Sarwar, Ghulam ^a   Tse, Tracy ^a   Sladden, Timothy M ^c   Hii, Esmond ^c   Yerkovich, Stephanie T ^a,c   Hopkins, Peter M ^a,c   Chambers, Daniel C ^a,c  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b WAIKATO HOSPITAL   (New Zealand)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

chronic lung allograft dysfunction; CLAD; death; erratic tacrolimus levels; lung transplant

Indexed keywords

PANCREAS ENZYME; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ALLOGRAFT; ARTICLE; BLOOD LEVEL; CHRONIC LUNG ALLOGRAFT DYSFUNCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DEATH; DRUG EXPOSURE; FEMALE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; ADVERSE EFFECTS; BLOOD; CHRONIC DISEASE; DOSE RESPONSE; FOLLOW UP; GRAFT REJECTION; MIDDLE AGED; NEW ZEALAND; PROGNOSIS; QUEENSLAND; RISK FACTOR; SURVIVAL RATE; TRENDS;

ADULT; ALLOGRAFTS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; NEW ZEALAND; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUEENSLAND; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TACROLIMUS;

EID: 84946480273     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2015.05.028     Document Type: Article

References (37)

1. C.M. Burke, J. Theodore, K.D. Dawkins, and et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation Chest 86 1984 824 829
2. C.A. Finlen Copeland, L.D. Snyder, and et al. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients Am J Respir Crit Care Med 182 2010 784 789
3. M.W. Gerbase, P.M. Soccal, A. Spiliopoulos, L.P. Nicod, and T. Rochat Long-term health-related quality of life and walking capacity of lung recipients with and without bronchiolitis obliterans syndrome J Heart Lung Transplant 27 2008 898 904
4. C. Kugler, S. Fischer, J. Gottlieb, and et al. Health-related quality of life in two hundred-eighty lung transplant recipients J Heart Lung Transplant 24 2005 2262 2268
5. H. Reichenspurner, R.E. Girgis, R.C. Robbins, and et al. Obliterative bronchiolitis after lung and heart-lung transplantation Ann Thorac Surg 60 1995 1845 1853
6. H. Reichenspurner, R.E. Girgis, R.C. Robbins, and et al. Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation Ann Thorac Surg 62 1996 1467 1472 discussion 72-3
7. A.R. Glanville, C.L. Aboyoun, A. Havryk, M. Plit, S. Rainer, and M.A. Malouf Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation Am J Respir Crit Care Med 177 2008 1033 1040
8. A.R. Glanville, C.L. Aboyoun, J.M. Morton, M. Plit, and M.A. Malouf Cyclosporine C2 target levels and acute cellular rejection after lung transplantation J Heart Lung Transplant 25 2006 928 934
9. J.M. Morton, C.L. Aboyoun, M.A. Malouf, M.L. Plit, and A.R. Glanville Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation J Heart Lung Transplant 23 2004 1035 1039
10. A. Trull, L. Steel, L. Sharples, and et al. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients Ther Drug Monit 21 1999 17 26
11. R.R. Hachem, R.D. Yusen, M.M. Chakinala, and et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation J Heart Lung Transplant 26 2007 1012 1018
12. R.J. Keenan, H. Konishi, A. Kawai, and et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation Ann Thorac Surg 60 1995 580 584 discussion 584-5
13. L. Penninga, E.I. Penninga, C.H. Moller, M. Iversen, D.A. Steinbruchel, and C. Gluud Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients Cochrane Database Syst Rev 2013 5 CD008817
14. H. Treede, A.R. Glanville, W. Klepetko, and et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation J Heart Lung Transplant 31 2012 797 804
15. H. Treede, W. Klepetko, H. Reichenspurner, and et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols J Heart Lung Transplant 20 2001 511 517
16. R.D. Yusen, J.D. Christie, L.B. Edwards, and et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report-2013; focus theme: age J Heart Lung Transplant 32 2013 965 978
17. W.J. Jusko, A.W. Thomson, J. Fung, and et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506) Ther Drug Monit 17 1995 606 614
18. H. Reichenspurner Overview of tacrolimus-based immunosuppression after heart or lung transplantation J Heart Lung Transplant 24 2005 119 130
19. H. Reichenspurner, F. Kur, H. Treede, and et al. Optimization of the immunosuppressive protocol after lung transplantation Transplantation 68 1999 67 71
20. H. Reichenspurner, F. Kur, H. Treede, and et al. Tacrolimus-based immunosuppressive protocols in lung transplantation Transplan Proc 31 1999 171 172
21. D.O. Taylor, M.L. Barr, B.M. Meiser, S.M. Pham, R.M. Mentzer, and A.L. Gass Suggested guidelines for the use of tacrolimus in cardiac transplant recipients J Heart Lung Transplant 20 2001 734 738
22. A. Zuckermann, H. Reichenspurner, T. Birsan, and et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial J Thorac Cardiovasc Surg 125 2003 891 900
23. C.Y. Chiang, H.G. Schneider, B.J. Levvey, L. Mitchell, and G.I. Snell Tacrolimus level variability is a novel measure associated with increased acute rejection in lung transplant (LTx) recipients J Heart Lung Transplant 32 2013 S170
24. L.C. Borra, J.I. Roodnat, J.A. Kal, R.A. Mathot, W. Weimar, and T. van Gelder High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation Nephrol Dial Transplant 25 2010 2757 2763
25. S.R. Lieber, and M.L. Volk Non-adherence and graft failure in adult liver transplant recipients Dig Dis Sci 58 2013 824 834
26. S.M. Pollock-BarZiv, Y. Finkelstein, C. Manlhiot, and et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children Pediatr Transplant 14 2010 968 975
27. M. Estenne, J.R. Maurer, A. Boehler, and et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria J Heart Lung Transplant 21 2002 297 310
28. K.L. Napoli Is microparticle enzyme-linked immunoassay (MEIA) reliable for use in tacrolimus TDM? Comparison of MEIA to liquid chromatography with mass spectrometric detection using longitudinal trough samples from transplant recipients Ther Drug Monit 28 2006 491 504
29. V.L. Venkat, T.G. Nick, Y. Wang, and J.C. Bucuvalas An objective measure to identify pediatric liver transplant recipients at risk for late allograft rejection related to non-adherence Pediatr Transplant 12 2008 67 72
30. C. Monchaud, and P. Marquet Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I Clin Pharmacokinet 48 2009 419 462
31. O.H. Bosma, K.M. Vermeulen, E.A. Verschuuren, M.E. Erasmus, and W. van der Bij Adherence to immunosuppression in adult lung transplant recipients: prevalence and risk factors J Heart Lung Transplant 30 2011 1275 1280
32. D.A. Hesselink, R.H. van Schaik, I.P. van der Heiden, and et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin Pharmacol Ther 74 2003 245 254
33. I.A. MacPhee, S. Fredericks, T. Tai, and et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation Am J Transplant 4 2004 914 919
34. H. Zheng, A. Zeevi, E. Schuetz, and et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism J Clin Pharmacol 44 2004 135 140
35. L. Rojas, I. Neumann, M.J. Herrero, and et al. Effect of CYP3A5∗3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies Pharmacogenomics J 15 2015 38 48
36. C.J. Li, L. Li, L. Lin, and et al. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients PLoS One 9 2014 e86206
37. R.P. Rapp Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions Ann Pharmacother 32 1998 785 793